Literature DB >> 15193393

Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526.

Venkat Rao1, Matthew E Hinz, Brian A Roberts, Donald Fine.   

Abstract

A hazard assessment of Venezuelan equine encephalitis (VEE) virus sub-types and vaccine candidates was performed according to standard risk assessment procedures. Data from published literature demonstrates a considerable degree of safety of V3526 when compared to TC-83 vaccine, the protective measure that has been used to protect laboratory workers for over four decades. V3526 is a new recombinant vaccine candidate that is a vastly different product with a diminished hazard to public health and the general environment. A weight-of-evidence (WOE)-based scheme was employed to assign weights for relevance, quality, and adequacy of evidence in published literature on medical pathology, epidemiology, pre-clinical investigational studies, and environmental studies. The results of this assessment indicated that V3526 has a low adverse impact on public health and the general environment. Although there are currently no human infectivity or pathogenicity data for V3526, existing evidence from published experimental animal studies reveals a diminished hazard for environmental transmission and distribution. Recently, the US Centers for Disease Control and Prevention (CDC) excluded V3526 from select agent requirements set forth under the Health and Human Services (HHS) regulations in Title 42 C.F.R. Part 73 and the US Department Agriculture (USDA) regulations set forth in Title 7 C.F.R. Part 331 and Title 9 C.F.R. Part 121. This paper summarizes the background, rationale, and hazard analysis used for assessing the environmental hazard of the VEE vaccine candidate strain V3526.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193393     DOI: 10.1016/j.vaccine.2003.09.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 2.  Vaccines for Venezuelan equine encephalitis.

Authors:  Slobodan Paessler; Scott C Weaver
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 3.  North American encephalitic arboviruses.

Authors:  Larry E Davis; J David Beckham; Kenneth L Tyler
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

Review 4.  Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.

Authors:  Anuj Sharma; Barbara Knollmann-Ritschel
Journal:  Viruses       Date:  2019-02-18       Impact factor: 5.048

5.  Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A.

Authors:  Anne Beall; Boyd Yount; Chun-Ming Lin; Yixuan Hou; Qiuhong Wang; Linda Saif; Ralph Baric
Journal:  mBio       Date:  2016-01-05       Impact factor: 7.867

6.  Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.

Authors:  Sudhakar Agnihothram; Vineet D Menachery; Boyd L Yount; Lisa C Lindesmith; Trevor Scobey; Alan Whitmore; Alexandra Schäfer; Mark T Heise; Ralph S Baric
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.